Browse MIF

Summary
SymbolMIF
Namemacrophage migration inhibitory factor (glycosylation-inhibiting factor)
Aliases GLIF; MMIF; L-dopachrome isomerase; phenylpyruvate tautomerase; Glycosylation-inhibiting factor; Macrophage ......
Chromosomal Location22q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted Cytoplasm Note=Does not have a cleavable signal sequence and is secreted via a specialized, non-classical pathway. Secreted by macrophages upon stimulation by bacterial lipopolysaccharide (LPS), or by M.tuberculosis antigens.
Domain PF01187 Macrophage migration inhibitory factor (MIF)
Function

Pro-inflammatory cytokine. Involved in the innate immune response to bacterial pathogens. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. Counteracts the anti-inflammatory activity of glucocorticoids. Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known. It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity.

> Gene Ontology
 
Biological Process GO:0001516 prostaglandin biosynthetic process
GO:0001776 leukocyte homeostasis
GO:0001782 B cell homeostasis
GO:0001783 B cell apoptotic process
GO:0001819 positive regulation of cytokine production
GO:0002237 response to molecule of bacterial origin
GO:0002260 lymphocyte homeostasis
GO:0002274 myeloid leukocyte activation
GO:0002367 cytokine production involved in immune response
GO:0002440 production of molecular mediator of immune response
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002700 regulation of production of molecular mediator of immune response
GO:0002702 positive regulation of production of molecular mediator of immune response
GO:0002718 regulation of cytokine production involved in immune response
GO:0002720 positive regulation of cytokine production involved in immune response
GO:0002831 regulation of response to biotic stimulus
GO:0002833 positive regulation of response to biotic stimulus
GO:0002901 mature B cell apoptotic process
GO:0002902 regulation of B cell apoptotic process
GO:0002903 negative regulation of B cell apoptotic process
GO:0002905 regulation of mature B cell apoptotic process
GO:0002906 negative regulation of mature B cell apoptotic process
GO:0006631 fatty acid metabolic process
GO:0006633 fatty acid biosynthetic process
GO:0006636 unsaturated fatty acid biosynthetic process
GO:0006690 icosanoid metabolic process
GO:0006692 prostanoid metabolic process
GO:0006693 prostaglandin metabolic process
GO:0006820 anion transport
GO:0006869 lipid transport
GO:0007050 cell cycle arrest
GO:0007568 aging
GO:0007569 cell aging
GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage
GO:0009306 protein secretion
GO:0010737 protein kinase A signaling
GO:0010738 regulation of protein kinase A signaling
GO:0010739 positive regulation of protein kinase A signaling
GO:0010876 lipid localization
GO:0010948 negative regulation of cell cycle process
GO:0015711 organic anion transport
GO:0015718 monocarboxylic acid transport
GO:0015732 prostaglandin transport
GO:0015908 fatty acid transport
GO:0015909 long-chain fatty acid transport
GO:0016053 organic acid biosynthetic process
GO:0018105 peptidyl-serine phosphorylation
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018209 peptidyl-serine modification
GO:0018212 peptidyl-tyrosine modification
GO:0030330 DNA damage response, signal transduction by p53 class mediator
GO:0030888 regulation of B cell proliferation
GO:0030890 positive regulation of B cell proliferation
GO:0031663 lipopolysaccharide-mediated signaling pathway
GO:0031664 regulation of lipopolysaccharide-mediated signaling pathway
GO:0031666 positive regulation of lipopolysaccharide-mediated signaling pathway
GO:0032103 positive regulation of response to external stimulus
GO:0032303 regulation of icosanoid secretion
GO:0032305 positive regulation of icosanoid secretion
GO:0032306 regulation of prostaglandin secretion
GO:0032308 positive regulation of prostaglandin secretion
GO:0032309 icosanoid secretion
GO:0032310 prostaglandin secretion
GO:0032368 regulation of lipid transport
GO:0032370 positive regulation of lipid transport
GO:0032496 response to lipopolysaccharide
GO:0032602 chemokine production
GO:0032642 regulation of chemokine production
GO:0032722 positive regulation of chemokine production
GO:0032844 regulation of homeostatic process
GO:0032845 negative regulation of homeostatic process
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0033028 myeloid cell apoptotic process
GO:0033032 regulation of myeloid cell apoptotic process
GO:0033033 negative regulation of myeloid cell apoptotic process
GO:0033135 regulation of peptidyl-serine phosphorylation
GO:0033138 positive regulation of peptidyl-serine phosphorylation
GO:0033559 unsaturated fatty acid metabolic process
GO:0033674 positive regulation of kinase activity
GO:0042100 B cell proliferation
GO:0042113 B cell activation
GO:0042116 macrophage activation
GO:0042770 signal transduction in response to DNA damage
GO:0042771 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator
GO:0043030 regulation of macrophage activation
GO:0043270 positive regulation of ion transport
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0043516 regulation of DNA damage response, signal transduction by p53 class mediator
GO:0043518 negative regulation of DNA damage response, signal transduction by p53 class mediator
GO:0043900 regulation of multi-organism process
GO:0043902 positive regulation of multi-organism process
GO:0044070 regulation of anion transport
GO:0044283 small molecule biosynthetic process
GO:0045786 negative regulation of cell cycle
GO:0045787 positive regulation of cell cycle
GO:0045860 positive regulation of protein kinase activity
GO:0046394 carboxylic acid biosynthetic process
GO:0046456 icosanoid biosynthetic process
GO:0046457 prostanoid biosynthetic process
GO:0046651 lymphocyte proliferation
GO:0046942 carboxylic acid transport
GO:0048144 fibroblast proliferation
GO:0048145 regulation of fibroblast proliferation
GO:0048146 positive regulation of fibroblast proliferation
GO:0048872 homeostasis of number of cells
GO:0050482 arachidonic acid secretion
GO:0050663 cytokine secretion
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0050715 positive regulation of cytokine secretion
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0050864 regulation of B cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050871 positive regulation of B cell activation
GO:0050900 leukocyte migration
GO:0050918 positive chemotaxis
GO:0051047 positive regulation of secretion
GO:0051222 positive regulation of protein transport
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051259 protein oligomerization
GO:0051260 protein homooligomerization
GO:0061078 positive regulation of prostaglandin secretion involved in immune response
GO:0061081 positive regulation of myeloid leukocyte cytokine production involved in immune response
GO:0061082 myeloid leukocyte cytokine production
GO:0070206 protein trimerization
GO:0070207 protein homotrimerization
GO:0070227 lymphocyte apoptotic process
GO:0070228 regulation of lymphocyte apoptotic process
GO:0070229 negative regulation of lymphocyte apoptotic process
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0071156 regulation of cell cycle arrest
GO:0071157 negative regulation of cell cycle arrest
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071396 cellular response to lipid
GO:0071715 icosanoid transport
GO:0071887 leukocyte apoptotic process
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0072330 monocarboxylic acid biosynthetic process
GO:0072331 signal transduction by p53 class mediator
GO:0072332 intrinsic apoptotic signaling pathway by p53 class mediator
GO:0072567 chemokine (C-X-C motif) ligand 2 production
GO:0090237 regulation of arachidonic acid secretion
GO:0090238 positive regulation of arachidonic acid secretion
GO:0090323 prostaglandin secretion involved in immune response
GO:0090342 regulation of cell aging
GO:0090344 negative regulation of cell aging
GO:0097193 intrinsic apoptotic signaling pathway
GO:1901796 regulation of signal transduction by p53 class mediator
GO:1901797 negative regulation of signal transduction by p53 class mediator
GO:1902165 regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator
GO:1902166 negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator
GO:1902229 regulation of intrinsic apoptotic signaling pathway in response to DNA damage
GO:1902230 negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage
GO:1902253 regulation of intrinsic apoptotic signaling pathway by p53 class mediator
GO:1902254 negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator
GO:1902532 negative regulation of intracellular signal transduction
GO:1903532 positive regulation of secretion by cell
GO:1903793 positive regulation of anion transport
GO:1903963 arachidonate transport
GO:1904951 positive regulation of establishment of protein localization
GO:2000106 regulation of leukocyte apoptotic process
GO:2000107 negative regulation of leukocyte apoptotic process
GO:2000191 regulation of fatty acid transport
GO:2000193 positive regulation of fatty acid transport
GO:2000341 regulation of chemokine (C-X-C motif) ligand 2 production
GO:2000343 positive regulation of chemokine (C-X-C motif) ligand 2 production
GO:2001020 regulation of response to DNA damage stimulus
GO:2001021 negative regulation of response to DNA damage stimulus
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001242 regulation of intrinsic apoptotic signaling pathway
GO:2001243 negative regulation of intrinsic apoptotic signaling pathway
Molecular Function GO:0004167 dopachrome isomerase activity
GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0016853 isomerase activity
GO:0016860 intramolecular oxidoreductase activity
GO:0016862 intramolecular oxidoreductase activity, interconverting keto- and enol-groups
GO:0016863 intramolecular oxidoreductase activity, transposing C=C bonds
GO:0042056 chemoattractant activity
GO:0050178 phenylpyruvate tautomerase activity
Cellular Component GO:0043209 myelin sheath
> KEGG and Reactome Pathway
 
KEGG hsa00350 Tyrosine metabolism
hsa00360 Phenylalanine metabolism
Reactome R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6798695: Neutrophil degranulation
Summary
SymbolMIF
Namemacrophage migration inhibitory factor (glycosylation-inhibiting factor)
Aliases GLIF; MMIF; L-dopachrome isomerase; phenylpyruvate tautomerase; Glycosylation-inhibiting factor; Macrophage ......
Chromosomal Location22q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MIF and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between MIF and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26603621MelanomaInhibit immunity (T cell function)These findings indicate that monocyte-derived MIF is centrally involved in human monocytic MDSC induction/immunosuppressive function and that therapeutic targeting of MIF may provide a novel means of inducing antitumor DC responses in late-stage melanoma patients.
27157615Brain NeoplasmInhibit immunityThe inhibition of MIF signaling or its receptor CD74 promotes IFN-γ release and amplifies tumor death either through pharmacological inhibition or through siRNA-mediated knockdown.
23125418Breast carcinomaInhibit immunity; immunotherapy targetSpecifically, MIF increases the prevalence of a highly immune suppressive subpopulation of myeloid-derived suppressor cells (MDSCs) within the tumor. In vitro, MIF promotes differentiation of myeloid cells into the same population of MDSCs. Pharmacologic inhibition of MIF reduces MDSC accumulation in the tumor similar to MIF depletion and blocks the MIF-dependent in vitro differentiation of MDSCs. Our results demonstrate that MIF is a therapeutically targetable mechanism for control of tumor growth and metastasis through regulation of the host immune response and support the potential utility of MIF inhibitors, either alone or in combination with standard tumor-targeting therapeutic or immunotherapy approaches.
23390297MelanomaInhibit immunity (T cell function)Finally, we report for the first time, to our knowledge, that our previously discovered MIF small molecule antagonist, 4-iodo-6-phenylpyrimidine, recapitulates MIF deficiency in vitro and in vivo, and attenuates tumor-polarized macrophage alternative activation, immunosuppression, neoangiogenesis, and melanoma tumor outgrowth.
18641325NeuroblastomaInhibit immunity (T cell function)Expression of macrophage migration inhibitory factor by neuroblastoma leads to the inhibition of antitumor T cell reactivity in vivo. We found that MIF expression in neuroblastoma inhibits T cell proliferation in vitro, raising the possibility that MIF promotes tumorigenesis, in part, by suppressing antitumor immunity.
18490733Ovarian CarcinomaInhibit immunity (NK cell function)The proinflammatory cytokine macrophage migration inhibitory factor (MIF) stimulates tumor cell proliferation, migration, and metastasis; promotes tumor angiogenesis; suppresses p53-mediated apoptosis; and inhibits antitumor immunity by largely unknown mechanisms. Functionally, we find that MIF may contribute to the immune escape of ovarian carcinoma by transcriptionally down-regulating NKG2D in vitro and in vivo which impairs NK cell cytotoxicity toward tumor cells.
22972922Colon CarcinomaInhibit immunityThe results showed that the tumor growth rate was significantly lower in MIF knockout (MIF(-/-)) mice than in wild-type (MIF(+/+)) mice. Flow cytometric analysis of both spleen and tumor cells revealed that MIF(-/-) mice had significantly lower levels of tumor-associated CD4(+)Tregs than MIF(+/+) mice. The splenic cells of MIF(-/-) mice also showed a decrease in CD8(+)Tregs, which was accompanied by an increase in CD8-induced tumor cytotoxicity.
21773885GliomaInhibit immunityQuantitative RT-PCR showed that MIF mRNA expression was elevated up to 800-fold in malignant glioma cells compared with normal brain. Stable knockdown of MIF by shRNA in glioma cells significantly increased tumour cell susceptibility towards NK cell-mediated cytotoxicity. We thus propose that human glioma cell-derived MIF contributes to the immune escape of malignant gliomas by counteracting NK and cytotoxic T-cell-mediated tumour immune surveillance.
29875777Metastatic MelanomaInhibit immunityBlockade of MIF-CD74 Signalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response Against Metastatic Melanoma. Interfering with MIF-CD74 signaling on MOs and DCs leads to a decrease in the expression of immunosuppressive factors from MOs and an increase in the capacity of DCs to activate cytotoxic T cells.
Summary
SymbolMIF
Namemacrophage migration inhibitory factor (glycosylation-inhibiting factor)
Aliases GLIF; MMIF; L-dopachrome isomerase; phenylpyruvate tautomerase; Glycosylation-inhibiting factor; Macrophage ......
Chromosomal Location22q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MIF in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMIF
Namemacrophage migration inhibitory factor (glycosylation-inhibiting factor)
Aliases GLIF; MMIF; L-dopachrome isomerase; phenylpyruvate tautomerase; Glycosylation-inhibiting factor; Macrophage ......
Chromosomal Location22q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MIF in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4990.416
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4470.921
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.5210.885
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.310.627
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.10.961
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8350.764
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1030.968
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.8610.829
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0120.906
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MIF in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMIF
Namemacrophage migration inhibitory factor (glycosylation-inhibiting factor)
Aliases GLIF; MMIF; L-dopachrome isomerase; phenylpyruvate tautomerase; Glycosylation-inhibiting factor; Macrophage ......
Chromosomal Location22q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MIF. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMIF
Namemacrophage migration inhibitory factor (glycosylation-inhibiting factor)
Aliases GLIF; MMIF; L-dopachrome isomerase; phenylpyruvate tautomerase; Glycosylation-inhibiting factor; Macrophage ......
Chromosomal Location22q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MIF. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MIF.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMIF
Namemacrophage migration inhibitory factor (glycosylation-inhibiting factor)
Aliases GLIF; MMIF; L-dopachrome isomerase; phenylpyruvate tautomerase; Glycosylation-inhibiting factor; Macrophage ......
Chromosomal Location22q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MIF. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMIF
Namemacrophage migration inhibitory factor (glycosylation-inhibiting factor)
Aliases GLIF; MMIF; L-dopachrome isomerase; phenylpyruvate tautomerase; Glycosylation-inhibiting factor; Macrophage ......
Chromosomal Location22q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MIF expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMIF
Namemacrophage migration inhibitory factor (glycosylation-inhibiting factor)
Aliases GLIF; MMIF; L-dopachrome isomerase; phenylpyruvate tautomerase; Glycosylation-inhibiting factor; Macrophage ......
Chromosomal Location22q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MIF and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMIF
Namemacrophage migration inhibitory factor (glycosylation-inhibiting factor)
Aliases GLIF; MMIF; L-dopachrome isomerase; phenylpyruvate tautomerase; Glycosylation-inhibiting factor; Macrophage ......
Chromosomal Location22q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MIF collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting MIF.
ID Name Drug Type Targets #Targets
DB018803,4-Dihydroxycinnamic AcidSmall MoleculeMIF1
DB027287-Hydroxy-2-Oxo-Chromene-3-Carboxylic Acid Ethyl EsterSmall MoleculeMIF1
DB04272Citric AcidSmall MoleculeAKR1B1, ANG, APRT, BHMT, C8G, CPB1, CS, CTDSP1, GNMT, HGS, HS3ST3A ......23
DB077183-(4-HYDROXY-PHENYL)PYRUVIC ACIDSmall MoleculeF2, MIF2
DB078883-(4-HYDROXYPHENYL)-4,5-DIHYDRO-5-ISOXAZOLE-ACETIC ACID METHYL ESTERSmall MoleculeMIF1
DB083334-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIMESmall MoleculeMIF1
DB083343-FLUORO-4-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIMESmall MoleculeMIF1
DB083354-HYDROXYBENZALDEHYDE O-(3,3-DIMETHYLBUTANOYL)OXIMESmall MoleculeMIF1
DB087656-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDESmall MoleculeCA2, MIF2